|
US6211245B1
(en)
|
1993-02-08 |
2001-04-03 |
Nps Pharmaceuticals, Inc. |
Compounds active at a novel site on receptor-operated calcium channels useful for treatment of neurological disorders and diseases
|
|
US6017965A
(en)
*
|
1993-02-08 |
2000-01-25 |
Nps Pharmaceuticals, Inc. |
Compounds active at a novel site on receptor-operated calcium channels useful for treatment of neurological disorders and diseases
|
|
US6750244B2
(en)
|
1993-02-08 |
2004-06-15 |
Nps Pharmaceuticals, Inc. |
Compounds active at a novel site on receptor-operated calcium channels useful for treatment of neurological disorders and diseases
|
|
US6071970A
(en)
*
|
1993-02-08 |
2000-06-06 |
Nps Pharmaceuticals, Inc. |
Compounds active at a novel site on receptor-operated calcium channels useful for treatment of neurological disorders and diseases
|
|
US7087765B2
(en)
|
1995-06-07 |
2006-08-08 |
Nps Pharmaceuticals, Inc. |
Compounds active at a novel site on receptor-operated calcium channels useful for treatment of neurological disorders and diseases
|
|
DE4426245A1
(de)
|
1994-07-23 |
1996-02-22 |
Gruenenthal Gmbh |
1-Phenyl-3-dimethylamino-propanverbindungen mit pharmakologischer Wirkung
|
|
US6262115B1
(en)
*
|
1995-05-22 |
2001-07-17 |
Alza Coporation |
Method for the management of incontinence
|
|
US5912268A
(en)
*
|
1995-05-22 |
1999-06-15 |
Alza Corporation |
Dosage form and method for treating incontinence
|
|
EP0912494A1
(en)
*
|
1996-06-07 |
1999-05-06 |
Nps Pharmaceuticals, Inc. |
Coumpounds active at a novel site on receptor-operated calcium channels useful for treatment of neurological disorders and diseases
|
|
EP0920306A2
(en)
|
1996-07-12 |
1999-06-09 |
Leukosite, Inc. |
Chemokine receptor antagonists and methods of use therefor
|
|
WO1998056752A1
(en)
*
|
1997-06-11 |
1998-12-17 |
Nps Pharmaceuticals, Inc. |
Compounds active at a novel site on receptor-operated calcium channels useful for treatment of neurological disorders and diseases
|
|
US6679859B1
(en)
|
1997-10-24 |
2004-01-20 |
Alliance Pharmaceutical Corp. |
Amelioration of ischemic damage using synthetic oxygen carriers
|
|
WO1999042480A1
(en)
*
|
1998-02-20 |
1999-08-26 |
Zeneca Limited |
Analgesic peptides from venom of grammostola spatulata and use thereof
|
|
EP0957073A1
(en)
|
1998-05-12 |
1999-11-17 |
Schwarz Pharma Ag |
Novel derivatives of 3,3-diphenylpropylamines
|
|
ATE355054T1
(de)
*
|
1998-07-13 |
2006-03-15 |
Nps Pharma Inc |
Verfahren und verbindungen zur behandlung der depression
|
|
IT1304874B1
(it)
*
|
1998-07-17 |
2001-04-05 |
Univ Firenze |
Amminoalcoli,amminochetoni e loro derivati,loro preparazione ed usocome farmaci per le patologie del sistema nervoso centrale (snc) e
|
|
JP2002527414A
(ja)
|
1998-10-14 |
2002-08-27 |
オーソ−マクニール・フアーマシユーチカル・インコーポレーテツド |
１，２−ジ置換シクロプロパン
|
|
GB9907965D0
(en)
|
1999-04-09 |
1999-06-02 |
Glaxo Group Ltd |
Medical use
|
|
US7345019B1
(en)
*
|
1999-04-13 |
2008-03-18 |
The Kenneth S. Warren Institute, Inc. |
Modulation of excitable tissue function by peripherally administered erythropoietin
|
|
JP2003505508A
(ja)
*
|
1999-07-30 |
2003-02-12 |
バーテックス ファーマシューティカルズ インコーポレイテッド |
非環式又は環式アミド誘導体
|
|
US6548522B1
(en)
|
1999-10-12 |
2003-04-15 |
Hoffmann-La Roche Inc. |
Method for treating conditions related to the glutamate receptor using carboxylic acid amide derivatives
|
|
AUPQ926700A0
(en)
*
|
2000-08-08 |
2000-08-31 |
Coroneo, Minas Theodore |
Methods for preventing pressure induced apoptotic neural cell death
|
|
AU2006236018B2
(en)
*
|
2000-08-08 |
2009-10-01 |
Minas Theodore Coroneo |
Methods for preventing pressure induced apoptotic neural cell death
|
|
US7767643B2
(en)
|
2000-12-29 |
2010-08-03 |
The Kenneth S. Warren Institute, Inc. |
Protection, restoration, and enhancement of erythropoietin-responsive cells, tissues and organs
|
|
US20030072737A1
(en)
*
|
2000-12-29 |
2003-04-17 |
Michael Brines |
Tissue protective cytokines for the protection, restoration, and enhancement of responsive cells, tissues and organs
|
|
US20030005476A1
(en)
*
|
2001-03-29 |
2003-01-02 |
Allen Keith D. |
Delta opioid receptor disruptions, compositions and methods related thereto
|
|
US20060112439A1
(en)
*
|
2001-03-29 |
2006-05-25 |
Allen Keith D |
Delta opioid receptor disruptions, compositions and methods related thereto
|
|
US6649607B2
(en)
|
2001-05-18 |
2003-11-18 |
Vela Pharmaceuticals, Inc. |
Compositions and methods for treating or preventing convulsions or seizures
|
|
US7250394B2
(en)
*
|
2001-08-20 |
2007-07-31 |
Maiken Nedergaard |
Treatment of glial tumors with glutamate antagonists
|
|
EP1298581A1
(fr)
*
|
2001-09-27 |
2003-04-02 |
C.S.E.M. Centre Suisse D'electronique Et De Microtechnique Sa |
Procédé et dispositif pour calculer les valeurs des neurones d'un réseau neuronal
|
|
US7776314B2
(en)
|
2002-06-17 |
2010-08-17 |
Grunenthal Gmbh |
Abuse-proofed dosage system
|
|
CA2491567A1
(en)
*
|
2002-07-01 |
2004-01-08 |
The Kenneth S. Warren Institute, Inc. |
Recombinant tissue protective cytokines and encoding nucleic acids thereof for protection, restoration, and enhancement of responsive cells, tissues, and organs
|
|
US20040082543A1
(en)
*
|
2002-10-29 |
2004-04-29 |
Pharmacia Corporation |
Compositions of cyclooxygenase-2 selective inhibitors and NMDA receptor antagonists for the treatment or prevention of neuropathic pain
|
|
DE10315917A1
(de)
|
2003-04-08 |
2004-11-18 |
Schwarz Pharma Ag |
Hochreine Basen von 3,3-Diphenylpropylaminmonoestern
|
|
JP2007502865A
(ja)
*
|
2003-05-23 |
2007-02-15 |
ブリッジ ファーマ、インコーポレイテッド |
平滑筋鎮痙剤
|
|
GB0313612D0
(en)
*
|
2003-06-12 |
2003-07-16 |
Novartis Ag |
Organic compounds
|
|
DE10336400A1
(de)
|
2003-08-06 |
2005-03-24 |
Grünenthal GmbH |
Gegen Missbrauch gesicherte Darreichungsform
|
|
DE102005005446A1
(de)
|
2005-02-04 |
2006-08-10 |
Grünenthal GmbH |
Bruchfeste Darreichungsformen mit retardierter Freisetzung
|
|
DE10361596A1
(de)
|
2003-12-24 |
2005-09-29 |
Grünenthal GmbH |
Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform
|
|
US20070048228A1
(en)
|
2003-08-06 |
2007-03-01 |
Elisabeth Arkenau-Maric |
Abuse-proofed dosage form
|
|
KR20070008519A
(ko)
*
|
2003-09-29 |
2007-01-17 |
워렌 파마슈티칼즈 인코포레이티드 |
패혈증 및 유착 형성의 치료 및 예방용 조직 보호성사이토카인
|
|
EP2301569B1
(en)
*
|
2003-11-12 |
2018-05-02 |
Yeda Research and Development Co. Ltd. |
Vaccine and method for treatment of neurodegenerative diseases
|
|
KR20070004769A
(ko)
|
2004-02-27 |
2007-01-09 |
암젠 인코포레이션 |
대사 장애의 치료에 사용되는 화합물, 약제학적 조성물 및그 사용방법
|
|
EA013261B1
(ru)
*
|
2004-05-14 |
2010-04-30 |
Янссен Фармацевтика, Н.В. |
Опиоидные соединения, замещенные карбоксамидогруппой
|
|
DE102004032049A1
(de)
|
2004-07-01 |
2006-01-19 |
Grünenthal GmbH |
Gegen Missbrauch gesicherte, orale Darreichungsform
|
|
WO2006023883A2
(en)
|
2004-08-20 |
2006-03-02 |
University Of Virginia Patent Foundation |
T type calcium channel inhibitors
|
|
EP2359832A3
(en)
*
|
2004-09-18 |
2011-11-23 |
University of Maryland, Baltimore |
Therapeutic agents targeting the NCCA-ATP channel and methods of use thereof
|
|
DE102005005449A1
(de)
|
2005-02-04 |
2006-08-10 |
Grünenthal GmbH |
Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform
|
|
JP2009523705A
(ja)
|
2005-11-30 |
2009-06-25 |
エフ．ホフマン−ラ ロシュ アーゲー |
３−アミノ−１−アリールプロピルインドールの合成方法
|
|
DE102007011485A1
(de)
|
2007-03-07 |
2008-09-11 |
Grünenthal GmbH |
Darreichungsform mit erschwertem Missbrauch
|
|
AU2008276278A1
(en)
*
|
2007-07-17 |
2009-01-22 |
Allergan, Inc. |
Methods for treating anxiety
|
|
JP5592265B2
(ja)
*
|
2007-11-01 |
2014-09-17 |
アキュセラ インコーポレイテッド |
眼の疾患及び障害治療用のアミン誘導体化合物
|
|
US8383152B2
(en)
|
2008-01-25 |
2013-02-26 |
Gruenenthal Gmbh |
Pharmaceutical dosage form
|
|
TWI524904B
(zh)
|
2008-05-09 |
2016-03-11 |
歌林達股份有限公司 |
製備醫藥用固體劑型，尤指錠劑之方法，及製備固體劑型，尤指錠劑之前驅物之方法
|
|
EP2397126B1
(en)
|
2009-02-12 |
2014-11-19 |
SNU R & DB Foundation |
Pharmaceutical composition containing glur2-lacking ampar antagonist for preventing or treating psychiatric illnesses
|
|
CN101838235B
(zh)
*
|
2009-06-12 |
2013-08-07 |
重庆华邦制药有限公司 |
3-苯基-3＇-吡啶基丙烯胺类化合物及其合成方法
|
|
NZ596668A
(en)
|
2009-07-22 |
2013-09-27 |
Gruenenthal Chemie |
Oxidation-stabilized tamper-resistant dosage form
|
|
JP5667183B2
(ja)
|
2009-07-22 |
2015-02-12 |
グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング |
加熱溶融押出成型した制御放出性投与剤型
|
|
ES2486791T3
(es)
|
2010-09-02 |
2014-08-19 |
Grünenthal GmbH |
Forma de dosificación resistente a la manipulación que comprende una sal inorgánica
|
|
MX2013002293A
(es)
|
2010-09-02 |
2013-05-09 |
Gruenenthal Gmbh |
Forma de dosificacion resistente a alteracion que comprende un polimero anionico.
|
|
EA201400172A1
(ru)
|
2011-07-29 |
2014-06-30 |
Грюненталь Гмбх |
Устойчивая к разрушению таблетка, которая обеспечивает немедленное высвобождение лекарственного средства
|
|
PE20141650A1
(es)
|
2011-07-29 |
2014-11-22 |
Gruenenthal Chemie |
Tableta a prueba de alteracion que proporciona liberacion inmediata del farmaco
|
|
WO2013127831A1
(en)
|
2012-02-28 |
2013-09-06 |
Grünenthal GmbH |
Tamper-resistant dosage form comprising pharmacologically active compound and anionic polymer
|
|
ES2692944T3
(es)
|
2012-04-18 |
2018-12-05 |
Grünenthal GmbH |
Forma de dosificación farmacéutica resistente a la manipulación y resistente a la descarga rápida de la dosis
|
|
US10064945B2
(en)
|
2012-05-11 |
2018-09-04 |
Gruenenthal Gmbh |
Thermoformed, tamper-resistant pharmaceutical dosage form containing zinc
|
|
BR112015026549A2
(pt)
|
2013-05-29 |
2017-07-25 |
Gruenenthal Gmbh |
forma de dosagem à prova de violação contendo uma ou mais partículas
|
|
US9737490B2
(en)
|
2013-05-29 |
2017-08-22 |
Grünenthal GmbH |
Tamper resistant dosage form with bimodal release profile
|
|
AU2014289187B2
(en)
|
2013-07-12 |
2019-07-11 |
Grunenthal Gmbh |
Tamper-resistant dosage form containing ethylene-vinyl acetate polymer
|
|
AU2014356581C1
(en)
|
2013-11-26 |
2020-05-28 |
Grunenthal Gmbh |
Preparation of a powdery pharmaceutical composition by means of cryo-milling
|
|
MX2016014738A
(es)
|
2014-05-12 |
2017-03-06 |
Gruenenthal Gmbh |
Formulacion en capsula de liberacion inmediata resistente a alteraciones que comprende tapentadol.
|
|
CN106456550A
(zh)
|
2014-05-26 |
2017-02-22 |
格吕伦塔尔有限公司 |
避免乙醇剂量倾泻的多颗粒
|
|
BR112017021475A2
(pt)
|
2015-04-24 |
2018-07-10 |
Gruenenthal Gmbh |
forma de dosagem resistente à adulteração (tamper) com liberação imediata e resistência contra extração de solvente
|
|
US10471025B2
(en)
|
2015-05-26 |
2019-11-12 |
Technophage, Investigacao E Desenvolvimento Em Biotecnologia, Sa |
Compositions for use in treating parkinson's disease and related disorders
|
|
CA2998259A1
(en)
|
2015-09-10 |
2017-03-16 |
Grunenthal Gmbh |
Protecting oral overdose with abuse deterrent immediate release formulations
|
|
CN107311891B
(zh)
*
|
2017-06-08 |
2019-08-06 |
山东一航新材料科技有限公司 |
一种亚胺类除水剂的制备方法
|
|
US11466027B2
(en)
|
2019-07-03 |
2022-10-11 |
H. Lundbeck A/S |
Modulators of the NMDA receptor
|
|
US11358971B2
(en)
|
2019-07-03 |
2022-06-14 |
H. Lundbeck A/S |
Prodrugs of modulators of the NMDA receptor
|
|
JP2022550589A
(ja)
*
|
2019-10-01 |
2022-12-02 |
メモリアル スローン ケタリング キャンサー センター |
Ｉｄタンパク質の小分子阻害剤
|
|
WO2022232931A1
(en)
*
|
2021-05-05 |
2022-11-10 |
Kare Chemical Technologies Inc. |
Catalytic tryptamine processes and precursors
|